

## Supplementary material

**Supplemental Table 2.** Search strategies

**Supplemental Table 3.** Risk of bias table

**Supplemental Table 4.** Characteristics of included studies

**Supplemental Table 5.** Result of multiple linear regression analysis coefficients for logarithmic-transformed prevalence of thromboembolism

**Supplemental Table 6.** Comparison of clinical characteristics between patients with and without TE

**Supplemental Table 7.** Comparison of clinical characteristics between adult patients with and without TE

**Supplemental Figure 1.** Summaries of forest plots of the mean prevalence of arrhythmia and LVEF in patients with LVNC

**Supplemental Figure 2.** Funnel plot of the assessment of publication bias

**Supplemental Figure 3.** Forest plot of the mean prevalence of thromboembolism in the patients with LVNC according to subgroup analysis

**Supplemental Figure 4.** Forest plot of the mean incidence of thromboembolism in the patients with LVNC according to subgroup analysis

**Supplemental Figure 5.** Forest plot of the mean prevalence and incidence of thromboembolism in the patients with LVNC excluding studies in which antithrombotic treatment in more than 30% of patient's population

**Supplemental Figure 6.** Forest plot of the mean mortality rates in the patients with LVNC according to subgroup analysis

**Supplemental Figure 7.** Forest plot of the mean mortality and heart plantation rates in the patients with LVNC according to subgroup analysis

### References.

#### Supplemental Table 2. Search strategies

Search strategies using MEDLINE (Supplemental Table 1a), Embase (Supplemental Table 1b), and Cochrane Cochrane Central Register of Controlled Trial (Supplemental Table 1c) are shown below.

#### Supplemental Table 2a. Search strategy using MEDLINE

No.	Query	Hit retrieved
S5	((('isolated noncompaction of the ventricular myocardium'/exp) OR hypertrabeculation OR LVNC OR (left ventricular trabeculation) OR (left ventricular noncompaction) OR (left ventricular non-compaction) OR (noncompacted cardiomyopathy) OR (noncompacted myocardium) OR (noncompaction cardiomyopathy) OR (noncompaction myocardium))	6,800
S6	((non-compacted cardiomyopathy) OR (non-compacted myocardium) OR (non-compaction cardiomyopathy) OR (non-compaction myocardium) OR (noncompaction of left ventricular myocardium) OR (spongy myocardium))	2,770
S8	(warfarin OR anticoagulants OR aspirin OR apixaban OR edoxaban OR rivaroxaban OR (antithrombotic therapy) OR dabigatran)	433,156
S9	(thromboembolism OR thrombosis OR embolism)	1,034,463
S10	S6 OR S5	7227

S11	S10 AND S8	219
S12	S10 AND S9	738
S13	S12 OR S11	833
S14	(S12 OR S11) and (subt.exact("human"))	744

Supplemental Table 2b. Search strategy using Embase

No.	Query	Hit retrieved
S1	((('isolated noncompaction of the ventricular myocardium'/exp) OR hypertrabeculation OR LVNC OR (left ventricular trabeculation) OR (left ventricular noncompaction) OR (left ventricular non-compaction) OR (noncompacted cardiomyopathy) OR (noncompacted myocardium) OR (noncompaction cardiomyopathy) OR (noncompaction myocardium)) and (human(yes)))	3,754
S3	((non-compacted cardiomyopathy) OR (non-compacted myocardium) OR (non-compaction cardiomyopathy) OR (non-compaction myocardium) OR (noncompaction of left ventricular myocardium) OR (spongy myocardium)) and (human(yes))	1,842
S4	('warfarin'/exp OR 'anticoagulants'/exp OR 'aspirin'/exp OR apixaban OR edoxaban OR rivaroxaban OR (antithrombotic therapy) OR 'dabigatran'/exp) and (human(yes))	36,963
S5	(warfarin OR anticoagulants OR aspirin OR apixaban OR edoxaban OR rivaroxaban OR (antithrombotic therapy) OR dabigatran) and (human(yes))	208,200
S6	('thromboembolism'/exp OR 'thrombosis'/exp OR 'embolism'/exp) and (human(yes))	1
S7	(thromboembolism OR thrombosis OR embolism) and (human(yes))	509,254
S8	S3 OR S1	3,889
S9	S8 AND S5	184
S10	S8 AND S7	650
S11	S10 OR S9	731
S15	(S10 OR S9) and (rtype.exact("Article") AND subt.exact("human"))	339

Supplemental Table 2c. Search strategy using Cochrane Central Register of Controlled Trial

No.	Query	Hit retrieved
#1	MeSH descriptor: [Isolated Noncompaction of the Ventricular Myocardium] explode all trees	0
#2	hypertrabeculation	0
#3	LVNC	1
#4	left ventricular trabeculation	3
#5	left ventricular noncompaction	6
#6	left ventricular non-compaction	5
#7	noncompacted cardiomyopathy	2
#8	noncompacted myocardium	1
#9	noncompaction cardiomyopathy	7
#10	noncompaction myocardium	4

#11	non-compacted cardiomyopathy	2
#12	non-compacted myocardium	1
#13	non-compaction cardiomyopathy	6
#14	non-compaction myocardium	4
#15	noncompaction of left ventricular myocardium	4
#16	spongy myocardium	0
#17	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR 15 OR 16	448,627
#18	MeSH descriptor: [Warfarin] explode all trees	1,700
#19	MeSH descriptor: [Anticoagulants] explode all trees	4,663
#20	MeSH descriptor: [Aspirin] explode all trees	5,935
#21	apixaban	978
#22	MeSH descriptor: [Dabigatran] explode all trees	312
#23	edoxaban	594
#24	rivaroxaban	1,738
#25	antithrombotic therapy	2,119
#26	#18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25	14,025
#27	MeSH descriptor: [Thromboembolism] explode all trees	2,112
#28	MeSH descriptor: [Thrombosis] explode all trees	4,841
#29	MeSH descriptor: [Embolism] explode all trees	1,427
#30	#27 OR #28 OR #29	7,272
#31	#17 AND #26	1
#32	#17 AND #30	0
#33	#31 OR #32	1

**Supplemental Table 3. Risk of bias table**

		Random sequence generation (selection bias)	Allocation sequence concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective outcome reporting (reporting bias)	Other bias
Chin TK	1990	?	?	+	+	?	?	+
Ichida F	1999	?	?	+	+	+	+	+
Wald R	2004	?	?	+	+	+	+	+
Lilje C	2006	?	?	+	+	+	+	+
Koh C	2009	?	?	+	+	+	+	+
Wang C	2017	?	?	+	+	+	+	+
Nucifora G	2017	?	?	+	+	?	?	+
van Waning J	2018	?	?	+	+	+	+	+
Takasaki A	2018	?	?	+	+	+	?	+
Hirono K	2020	?	?	+	+	+	?	+
Ritter M	1997	?	?	+	+	+	?	+
Oechslin EN	2000	?	?	+	+	+	+	+
Stollberger C	2005	+	+	+	+	?	+	+
Murphy RT	2005	?	?	+	+	+	+	+
Lofiego C	2007	?	?	+	+	+	+	+
Espinola-Zavaleta N	2006	?	?	+	+	+	+	+
Aras D	2006	?	?	+	+	+	+	+
Finsterer J	2008	?	?	+	+	+	+	+
Fazio G	2008	?	?	+	+	+	+	+
Yousef ZR	2009	?	?	+	+	?	?	+
Stanton C	2009	?	?	+	+	+	+	+
Shoji M	2010	?	?	+	+	?	?	+
Habib G	2011	?	?	+	+	+	+	+
Greutmann M	2012	?	?	+	+	+	+	+
Yun H	2011	?	?	+	+	?	?	+
Stollberger C	2013	?	?	+	+	+	?	+
Nikolić A	2012	?	?	+	+	?	?	+
Caliskan K	2012	?	?	+	+	+	?	+
Stacey R	2013	?	?	+	+	?	?	+
Tian T	2014	?	?	+	+	+	+	+
Peters F	2014	+	+	+	+	+	+	+
Li J	2015	?	?	+	+	+	+	+
Akhour S	2015	?	?	+	+	?	?	+
Stollberger C	2015	?	?	+	+	+	+	+
Amzulescu MS	2015	?	?	+	+	+	+	+
Minamisawa M	2016	?	?	+	+	?	?	+
Zhou H	2016	?	?	+	+	?	?	+
Andreini D	2016	?	?	+	+	+	+	+
Muser D	2017	?	?	+	+	+	+	+
Asfalou I	2017	?	?	+	+	+	+	+
Tavares de Melo MD	2017	?	?	+	+	?	?	+
Mazurkiewicz L	2017	?	?	+	+	+	+	+
Nucifora G	2017	?	?	+	+	?	?	+
Sedaghat-Hamedani F	2017	?	?	+	+	+	+	+
Salazar-Mendiguchía J	2019	?	?	+	+	+	+	+
Martinez H	2017	?	?	+	+	?	?	+
van Waning J	2018	?	?	+	+	+	+	+
Araujo-Filho JAB	2018	?	?	+	+	?	?	+
Sohns C	2019	?	?	+	+	?	?	+
van Waning JI	2019	?	?	+	+	+	+	+
Azevedo O	2019	?	?	+	+	+	+	+
Macaione F	2020	?	?	+	+	?	?	+
Asmakutlu O	2020	?	?	+	+	?	?	+
Rocon C	2020	?	?	+	+	+	+	+
Rapatz K	2020	?	?	+	+	+	+	+
Zemrak F	2020	?	?	+	+	?	?	+
Femia G	2020	?	?	+	+	+	+	+
Galizio N	2011	?	?	+	+	+	+	+
Pignatelli R	2003	?	?	+	+	+	+	+

According to the Cochrane Hand book for Systematic Reviews of Interventions, version 5.1.0. +: low risk of bias; - : high risk of bias; ?: unclear risk of bias.

**Supplemental Table 4. Characteristics of included studies**

Author	Year	Patients (n)	Age (years)	Male (%)	Follow-up period (years)	Diagnostic criteria	Echo/MRI	LVEF (%)	AF (%)	VT (%)	Anticoagulant	Antiplatelet	Anticoagulant/Antiplatelet (%)	Hx of TE (%)	TE events (%)
<b>Children</b>															
Chin[1]	1990	8	8.9 (0.9–22.5)	63.0	N/A	Chin	Echo	N/A	0	62.5	N/A	N/A	N/A	38.0	N/A
Ichida[2]	1999	27	5.0 (0–15.0)	55.6	6.0 (0–17.0)	Ichida	Echo	61.5 ± 11.6	3.7	0	N/A	N/A	N/A	N/A	0
Pignatelli[3]	2003	36	0.3 (0–17)	55.6	3.2 (0.5– 12.0)	Jenni	Echo	25 (18.0–32.0)	0	2.8	N/A	N/A	N/A	2.8	0
Wald[4]	2004	22	3.9 (0–16.0)	40.9	3.0 (0.1–16)	Jenni	Echo	34.0 (6.0–67)	0	9.1	N/A	N/A	N/A	N/A	0
Lilje[5]	2006	66	4.0 (0–21.0)	48.5	1.0 (0–4.3)	Chin, Jenni	Echo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	13.9
Koh[6]	2009	10	2.0 (0–12.0)	70.0	2.0 (0.2–3.0)	Jenni	Echo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0
Wang[7]	2017	205	3.6 (0–15.0)	53.7	4.6 (0–22.0)	Jenni	Echo	49.9 ± 2.1	N/A	N/A	N/A	N/A	N/A	N/A	4.9
Nucifora[8]	2017	12	15.0 ± 3.0	75.0	N/A	Petersen, Jacquire	MRI	64.0 ± 8.0	N/A	8.0	N/A	N/A	N/A	0	N/A
van Waning[9]	2018	52	7.0 (0–14.0)	52.0	5.0 (1.5–9.4)	Jenni, Petersen	UCG/MRI	N/A	10.0	6.0	N/A	N/A	N/A	2.0	4.0
Takasaki[10]	2018	82	0.8 (0–35.0)	56.1	4.8 (0–22.0)	Paterick	Echo	42.4 ± 3.5	N/A	N/A	N/A	N/A	N/A	3.7	N/A
Hirono[11]	2020	206	0.3 (0–16.0)	57.8	2.0 (0–33.0)	Paterick	Echo	47.1 ± 19.1	0	11.2	N/A	N/A	N/A	2.4	N/A
<b>Adults</b>															
Ritter[12]	1997	17	41.6 (18.0–71.0)	82.3	2.5 ± 2.3	Stollberger	Echo	N/A	29.4	11.8	N/A	N/A	N/A	5.9	24.0
Oechslin[13]	2000	34	42.0 ± 17.0	74.0	3.7 ± 3.3	Jenni	Echo	33.0 ± 13.0	26.0	41.0	N/A	N/A	N/A	N/A	24.0
Stollberger[14]	2005	62	53.0	86.0	N/A	Stollberger	Echo	FS 25.1	8.1	N/A	yes	N/A	6.5	1.6	10.0
Murphy[15]	2005	45	37.0 ± 17.0	62.2	2.7 (0.5–14.9)	Chin, Jenni	Echo	FS 21.0 ± 9.0	6.5	22.0	yes	N/A	60.0	N/A	4.0
Lofiego[16]	2007	65	42.0 ± 17.0	N/A	3.8 (0.5–16.1)	Jenni	Echo	31.0 ± 11.0	1.5	6.0	yes	N/A	52.3	N/A	5.0
Espinola-Zavaleta[17]	2006	53	43.2 ± 14.8	47.2	0.6 ± 0.4	Jenni	Echo	39.0 ± 18.5	5.7	7.5	N/A	N/A	N/A	N/A	5.7
Aras[18]	2006	67	41.0 ± 18.0	66.0	3.0 ± 1.1	Jenni	Echo	43.5 ± 14.4	12.0	36.0	N/A	yes	28.3	6.0	9.0
Finsterer[19]	2008	104	14.0–94.0	71.0	12.0	Stollberger	Echo	N/A	N/A	N/A	N/A	N/A	N/A	9.0	15.0
Fazio[20]	2008	238	41.5 (1.0–92.0)	58.0	7.3 (1.0–12.0)	Stollberger	Echo	24.6	N/A	N/A	N/A	N/A	N/A	14.0	2.1
Yousef[21]	2009	42	48.7 ± 2.3	59.5	N/A	Jenni	Echo	41.1 ± 14.8	28.6	N/A	N/A	N/A	N/A	14.0	N/A
Stanton[22]	2009	30	39.0 ± 19.5	60.0	2.5 ± 1.2	Jenni	Echo	41.0 ± 15.0	16.6	10.0	N/A	yes	30.0	0	0
Shoji[23]	2010	187	41.3 ± 16.8	65.8	N/A	Jenni	Echo	62.2	4.8	1.1	N/A	N/A	N/A	0.5	N/A
Habib[24]	2011	105	45.0 ± 17.0	66.0	2.3 ± 1.5	Jenni	Echo	46.0 ± 18.0	7.0	7.0	yes	N/A	29.2	4.0	8.5
Greutmann[25]	2012	132	41.0 ± 17.0	35.0	2.7 (0.1–19.4)	Jenni	Echo	41.0 ± 18.0	24.0	7.0	yes	yes	36.0	3.0	4.0
Yun[26]	2011	11	35.0 (15.0–58.0)	81.8	N/A	Petersen	MRI	40.0 (23.0–70.0)	0	0	N/A	N/A	N/A	9.1	N/A
Stollberger[27]	2013	169	52.9 ± 16.0	70.0	16.0	Stollberger	Echo	FS 24.2 ± 11.0	16.6	N/A	N/A	N/A	N/A	15.0	N/A
Nikolić[28]	2012	12	45.0 ± 15.0	58.3	N/A	Jenni	Echo	49.8 ± 8.0	33.3	25.0	N/A	N/A	N/A	0	N/A
Caliskan[29]	2012	84	40.0 (17.0–77.0)	47.6	5.3 (1.5–9.6)	Jenni	Echo	FS 20.8 ± 8.2	9.5	19.0	N/A	N/A	N/A	10.7	N/A
Stacey[30]	2013	122	57.0 ± 17.5	59.0	N/A	Jacquier	MRI	44.0 ± 16.0	N/A	4.9	N/A	N/A	N/A	8.2	N/A
Tian[31]	2014	106	46.0 ± 17.0	78.0	2.9 ± 2.1	Jenni	Echo	39.0 ± 14.0	13.0	2.0	yes	N/A	9.0	6.0	4.0
Peters[32]	2014	55	42.2 ± 11.5	38.2	1.4 ± 0.5	Jenni	Echo	29.6 ± 11.8	1.8	1.8	yes	N/A	29.1	16.3	1.8

Author	Year	Patients (n)	Age (years)	Male (%)	Follow-up period (years)	Diagnostic criteria	Echo/MRI	LVEF (%)	AF (%)	VT (%)	Anticoagulant	Antiplatelet	Anticoagulant/Antiplatelet (%)	Hx of TE (%)	TE events (%)
Li[33]	2015	20	42.5 (36.3–52.5)	60.0	1.1±0.5	Stollberger	Echo	32.0 (22.0–40.0)	5.0	5.0	yes	yes	60.0	N/A	0
Akhour[34]	2015	24	42.7 ± 13.1	66.7	N/A	Petersen	MRI	37.8 ± 13.9	16.7	20.8	N/A	N/A	N/A	4.2	N/A
Stöllberger[35]	2015	232	52.0 ± 17.0	69.0	6.0 ± 5.2	Stollberger	Echo	FS 25.0 ± 11.0	16.0	N/A	N/A	N/A	N/A	N/A	4.3
Amzulescu[36]	2015	59	52.0 ± 13.0	57.6	3.4 (1.5 – 6.3)	Petersen	MRI	24.1 ± 8.3	3.0	N/A	yes	yes	22.0	12.0	6.8
Minamisawa[37]	2016	23	54.9 ± 9.1	69.6	5.1	Jenni	Echo	27.4 ± 8.5	43.5	N/A	yes	N/A	43.4	8.7	N/A
Zhou[38]	2016	31	40.8 ± 4.8	61.3	N/A	Jenni	Echo	42.0 ± 5.9	N/A	N/A	N/A	N/A	N/A	6.5	N/A
Andreini[39]	2016	113	44.0 ± 17.0	62.0	4 ± 2	Jenni, Petersen	Echo /MRI	42.8 ± 16.2	N/A	N/A	yes	yes	5.0	N/A	4.4
Muser[40]	2017	9	42.0 ± 15.0	55.6	4.0 (1.0 – 11.0)	Jenni	Echo	40.0 ± 12.1	N/A	44.4	yes	N/A	66.6	N/A	11.1
Asfalou[41]	2017	23	47.0 ± 13.0	65.2	2.0	Jenni	Echo	27.0 ± 8.0	21.7	16.6	yes	N/A	28.6	N/A	4.3
Tavares de Melo[42]	2017	30	41.0 ± 12.0	53.0	N/A	Petersen	MRI	39.0 ± 14.0	N/A	33.0	yes	N/A	77.0	13.0	N/A
Mazurkiewicz[43]	2017	127	33.1 ± 8.8	61.4	2.2 ± 1.0	Grothoff	MRI	27.7 ± 6.8	11.8	N/A	N/A	N/A	N/A	8.7	1.6
Nucifora[8]	2017	20	35.0 ± 7.0	75.0	N/A	Petersen, Jacquiere	MRI	55.0 ± 14.0	N/A	10.0	N/A	N/A	N/A	10.0	N/A
Sedaghat-Hamedani[44]	2017	95	41.0 ± 14.4	70.6	5.1	Jenni, Stollberger	Echo	38.0 ± 15.3	29.4	35.3	N/A	N/A	N/A	N/A	10.3
Salazar-Mendiguchía[45]	2019	75	50.4 ± 14.8	68.0	5.0 (2.4 – 6.7)	Jenni	Echo	32.0 (29.0 – 34.0)	38.7	4.0	yes	yes	53.3	1.3	5.3
Martinez[46]	2017	13	N/A	N/A	N/A	Jenni	Echo	N/A	N/A	N/A	N/A	yes	N/A	8.0	N/A
van Waning[9]	2018	275	45.0 (33.0 – 56.0)	54.0	2.1 (0.3 – 4.8)	Jenni, Petersen	Echo /MRI	N/A	16.0	6.0	N/A	N/A	N/A	3.0	13.0
Araujo-Filho[47]	2018	36	41.0 ± 13.0	61.0	N/A	Petersen	MRI	42.0 ± 6.0	N/A	30.6	yes	N/A	55.6	8.3	N/A
Sohns[48]	2019	18	43.5 ± 18.0	66.7	5.2 ± 3.5	Jenni	Echo	35.0 ± 15.0	11.1	66.7	yes	N/A	77.8	27.8	N/A
van Waning[49]	2019	216	38.0 (23.0 – 52.0)	54.0	3.7 (0.8 – 7.8)	Jenni, Petersen, Grothoff	Echo /MRI	N/A	11.6	11.6	N/A	N/A	N/A	N/A	4.6
Azevedo[50]	2019	78	47.0 ± 17.0	62.8	4.4 ± 2.8	Jenni, Stollberger, Chin, Petersen Jacquiere	Echo /MRI	47.2 ± 15.2	13.5	21.6	N/A	N/A	N/A	5.1	11.5
Macaione[51]	2020	27	47.6 ± 22.6	77.8	N/A	Jenni, Petersen, Grothoff	Echo /MRI	48.5 ± 17.6	N/A	11.1	N/A	N/A	N/A	3.7	N/A
Asmakutlu[52]	2020	42	32.4 (18.0 – 63.0)	52.3	N/A	Stollberger, Petersen	Echo /MRI	50.3 (22.0 – 67.0)	4.7	11.9	N/A	N/A	N/A	14.2	N/A
Rocon[53]	2020	108	38.3 ± 15.5	48.1	5.8 ± 3.9	Chin, Jenni, Stollberger, Petersen	Echo /MRI	45.3 ± 14.6	N/A	61.7	N/A	N/A	N/A	N/A	17.0
Rapatz[54]	2020	113	57.0 (45.0 – 69.0)	76.0	6.1 ± 5.3	Stollberger	Echo	FS 20.0 (15.0 – 30.0)	20.0	N/A	N/A	N/A	N/A	12.0	6.0
Zemrak[55]	2020	142	N/A	N/A	N/A	Petersen	MRI	N/A	N/A	N/A	N/A	N/A	N/A	1.3	N/A
Femia[56]	2020	98	47.0 (31.0 – 65.0)	56.7	6.5 (5.5 – 7.5)	Petersen	MRI	81.2 ± 7.2	1.0	16.3	N/A	N/A	N/A	7.1	4.1
Galizio[57]	2011	80	41.0 ± 17.0	66.3	1.1 (0.5 – 2.1)	Chin, Jenni, Stollberger, Petersen	Echo /MRI	38.6 ± 11.4	N/A	18.8	N/A	N/A	N/A	N/A	3.75

Echo, echocardiography; MRI magnetic resonance imaging; LVEF, left ventricular ejection fraction; AF; atrial fibrillation; VT, ventricular tachycardia; Hx, history; TE, thromboembolism; N/A, not applicable; FS, fractional shortening.

**Supplemental Table 5. Result of multiple linear regression analysis coefficients for logarithmic-transformed prevalence of thromboembolism**

Model	Unstandardized coefficients				Standardized coefficients		P value	Variance Inflation Factor
	$\beta$	Standard error	Lower CI	Upper CI	$\beta$	T		
Constant	3.0518441	0.672898	1.5296435	4.5740446	0	4.54	0.0014	
Follow-up period (y)	0.386106	0.164966	0.0129269	0.7592851	0.730529	2.34	0.0440	1.8558142
LVEF (%)	-0.046194	0.017301	-0.085332	-0.007057	-0.83592	-2.67	0.0256	1.8671364
AF (%)	-0.053726	0.018199	-0.094894	-0.012558	-0.90918	-2.95	0.0162	1.8067165

CI, confidence interval; LVEF, left ventricular ejection fraction; AF; atrial fibrillation.

**Supplemental Table 6. Comparison of clinical characteristics between pediatric patients with and without TE**

	TE negative (n = 281)	TE positive (n = 6)	<i>P</i> value
Male	142	4	1.0000
FH	72	2	1.0000
CHD	37	0	1.0000
HF at diagnosis	154	5	0.2303
LVEF (%)	46.9 ± 18.9	30.3 ± 19.9	0.0648
LVEF<40%	89	4	0.0608
AF	2	0	1.0000
VT	29	1	0.4876
Anticoagulant	3	1	0.0298
Antiplatelet	7	0	1.0000

FX, family history; CHD, congenital heart disease; HF, heart failure; LVEF, left ventricular ejection fraction; AF, atrial fibrillation; VT, ventricular tachycardia









**Supplemental Table 7. Comparison of clinical characteristics between adult patients with and without TE**

	TE negative (n = 21)	TE positive (n = 5)	<i>P</i> value
Male	14	5	0.2782
FH	2	1	0.3333
CHD	0	0	1.0000
HF at diagnosis	7	3	0.3402
LVEF (%)	39.8 ± 13.8	40	1.0000
LVEF<40%	3	0	1.0000
AF	4	1	1.0000
VT	9	1	0.6169

FX, family history; CHD, congenital heart disease; HF, heart failure; LVEF, left ventricular ejection fraction; AF, atrial fibrillation; VT, ventricular tachycardia



**Supplemental Figure 1. Summaries of forest plots of the mean prevalence of arrhythmia and LVEF in patients with LVNC**

Mean prevalence of atrial fibrillation (AF) in pediatric (A) and adult patients (B). Mean prevalence of ventricular tachycardia (VT) in pediatric (C) and adult patients (D). Mean LVEF in pediatric (E) and adult patients (F).



**Supplemental Figure 2. Funnel plot of the assessment of publication bias for studies**

Funnel plot of the assessment of publication bias for studies regarding the prevalence (A) and incidence (B) of TE in the patients with LVNC

**A****B**







**Supplemental Figure 3. Forest plot of the mean prevalence of thromboembolism in the patients with LVNC according to subgroup analysis**

Mean prevalence of thromboembolism in studies with average LVEF &lt;40% (A) and &gt;40% (B).

Mean prevalence of thromboembolism in studies with mean follow-up period &lt;4years (C) and &gt;4years (D).

Mean prevalence of thromboembolism in studies with mean prevalence of AF &lt;10% (E) and prevalence of AF &gt;10% (F).

CI, confidence interval.

**A****B****C****D****E****F**

**Supplemental Figure 4. Forest plot of the mean incidence of thromboembolism in the patients with LVNC according to subgroup analysis**


Mean incidence of thromboembolism in studies with average LVEF <40% (A) and >40% (B).

Mean incidence of thromboembolism in studies with mean follow-up period <4years (C) and >4years (D).


Mean incidence of thromboembolism in studies with mean prevalence of AF <10% (E) and prevalence of AF >10% (F).

CI, confidence interval.


**A**




**B**




**C**




**D**



**E**



**F**




**Supplemental Figure 5. Forest plot of the mean prevalence and incidence of thromboembolism in the patients with LVNC excluding studies in which antithrombotic treatment in more than 30% of patient's population**

Mean prevalence of thromboembolism in all patients (A) and adult patients (B) with LVNC.


Mean incidence of thromboembolism in the whole aged (C) and adult patients (D) with LVNC.

CI, confidence interval.


**A**




**B**



**C**



**D**











**Supplemental Figure 6. Forest plot of the mean mortality rates in the patients with LVNC according to subgroup analysis**

The mean mortality rates in studies with average LVEF &lt;40% (A) and &gt;40% (B).

The mean mortality rates in studies with mean follow-up period &lt;4years (C) and &gt;4years (D).

The mean mortality rates in studies with mean prevalence of AF &lt;10% (E) and prevalence of AF &gt;10% (F).

CI, confidence interval.

**A****B****C****D****E****F**

**Supplemental Figure 7. Forest plot of the mean mortality and heart plantation rates in the patients with LVNC according to subgroup analysis**


The mean mortality and heart plantation rates in studies with average LVEF <40% (A) and >40% (B).

The mean mortality and heart plantation rates in studies with mean follow-up period <4years (C) and >4years (D).


The mean mortality and heart plantation rates in studies with mean prevalence of AF <10% (E) and prevalence of AF >10% (F).

CI, confidence interval.


**A**




**B**




**C**




**D**



**E**



**F**





## REFERENCES

- 1 Chin TK, Perloff JK, Williams RG, et al. Isolated noncompaction of left ventricular myocardium. A study of eight cases. *Circulation* 1990;**82**:507-13.
- 2 Ichida F, Hamamichi Y, Miyawaki T, et al. Clinical features of isolated noncompaction of the ventricular myocardium: long-term clinical course, hemodynamic properties, and genetic background. *J Am Coll Cardiol* 1999;**34**:233-40.
- 3 Pignatelli RH, McMahon CJ, Dreyer WJ, et al. Clinical characterization of left ventricular noncompaction in children: a relatively common form of cardiomyopathy. *Circulation* 2003;**108**:2672-8.
- 4 Wald R, Veldtman G, Golding F, et al. Determinants of outcome in isolated ventricular noncompaction in childhood. *Am J Cardiol* 2004;**94**:1581-4.
- 5 Lilje C, Razek V, Joyce JJ, et al. Complications of non-compaction of the left ventricular myocardium in a paediatric population: a prospective study. *Eur Heart J* 2006;**27**:1855-60.
- 6 Koh C, Lee PW, Yung TC, et al. Left ventricular noncompaction in children. *Congenit Heart Dis* 2009;**4**:288-94.
- 7 Wang C, Takasaki A, Watanabe Ozawa S, et al. Long-Term Prognosis of Patients With Left Ventricular Noncompaction- Comparison Between Infantile and Juvenile Types. *Circ J* 2017;**81**:694-700.
- 8 Nucifora G, Sree Raman K, Muser D, et al. Cardiac magnetic resonance evaluation of left ventricular functional, morphological, and structural features in children and adolescents vs. young adults with isolated left ventricular non-compaction. *Int J Cardiol* 2017;**246**:68-73.
- 9 van Waning JI, Caliskan K, Hoedemaekers YM, et al. Genetics, Clinical Features, and Long-Term Outcome of Noncompaction Cardiomyopathy. *J Am Coll Cardiol* 2018;**71**:711-22.
- 10 Takasaki A, Hirono K, Hata Y, et al. Sarcomere gene variants act as a genetic trigger underlying the development of left ventricular noncompaction. *Pediatr Res* 2018;**84**:733-42.
- 11 Hirono K, Hata Y, Miyao N, et al. Increased Burden of Ion Channel Gene Variants Is Related to Distinct Phenotypes in Pediatric Patients With Left Ventricular Noncompaction. *Circ Genom Precis Med* 2020;**13**:e002940.
- 12 Ritter M, Oechslin E, Sutsch G, et al. Isolated noncompaction of the myocardium in adults. *Mayo Clin Proc* 1997;**72**:26-31.
- 13 Oechslin EN, Attenhofer Jost CH, Rojas JR, et al. Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. *J Am Coll Cardiol* 2000;**36**:493-500.
- 14 Stollberger C, Finsterer J. Left ventricular hypertrabeculation/noncompaction and stroke or embolism. *Cardiology* 2005;**103**:68-72.
- 15 Murphy RT, Thaman R, Blanes JG, et al. Natural history and familial characteristics of isolated left ventricular non-compaction. *Eur Heart J* 2005;**26**:187-92.
- 16 Lofiego C, Biagini E, Pasquale F, et al. Wide spectrum of presentation and variable outcomes of isolated left ventricular non-compaction. *Heart* 2007;**93**:65-71.
- 17 Espinola-Zavaleta N, Soto ME, Castellanos LM, et al. Non-compacted cardiomyopathy: clinical-echocardiographic study. *Cardiovasc Ultrasound* 2006;**4**:35.
- 18 Aras D, Tufekcioglu O, Ergun K, et al. Clinical features of isolated ventricular noncompaction in adults long-term clinical course, echocardiographic properties, and predictors of left ventricular failure. *J Card Fail* 2006;**12**:726-33.
- 19 Finsterer J, Stollberger C, Molzer G, et al. Cerebrovascular events in left ventricular hypertrabeculation/noncompaction with and without myopathy. *Int J Cardiol* 2008;**130**:344-8.
- 20 Fazio G, Corrado G, Zachara E, et al. Anticoagulant drugs in noncompaction: a mandatory therapy? *J*

*Cardiovasc Med (Hagerstown)* 2008;**9**:1095-7.

- 21 Yousef ZR, Foley PW, Khadjooi K, et al. Left ventricular non-compaction: clinical features and cardiovascular magnetic resonance imaging. *BMC Cardiovasc Disord* 2009;**9**:37.
- 22 Stanton C, Bruce C, Connolly H, et al. Isolated left ventricular noncompaction syndrome. *Am J Cardiol* 2009;**104**:1135-8.
- 23 Shoji M, Yamashita T, Uejima T, et al. Electrocardiography characteristics of isolated non-compaction of ventricular myocardium in Japanese adult patients. *Circ J* 2010;**74**:1431-5.
- 24 Habib G, Charron P, Eicher JC, et al. Isolated left ventricular non-compaction in adults: clinical and echocardiographic features in 105 patients. Results from a French registry. *Eur J Heart Fail* 2011;**13**:177-85.
- 25 Greutmann M, Mah ML, Silversides CK, et al. Predictors of adverse outcome in adolescents and adults with isolated left ventricular noncompaction. *Am J Cardiol* 2012;**109**:276-81.
- 26 Yun H, Zeng MS, Jin H, et al. Isolated noncompaction of ventricular myocardium: a magnetic resonance imaging study of 11 patients. *Korean J Radiol* 2011;**12**:686-92.
- 27 Stollberger C, Wegner C, Finsterer J. CHADS2- and CHA2DS2VASc scores and embolic risk in left ventricular hypertrabeculation/noncompaction. *J Stroke Cerebrovasc Dis* 2013;**22**:709-12.
- 28 Nikolic A, Jovicic L, Tomic S, et al. Left ventricular noncompaction: clinical-echocardiographic study. *Vojnosanit Pregl* 2012;**69**:32-6.
- 29 Caliskan K, Ujvari B, Bauernfeind T, et al. The prevalence of early repolarization in patients with noncompaction cardiomyopathy presenting with malignant ventricular arrhythmias. *J Cardiovasc Electrophysiol* 2012;**23**:938-44.
- 30 Stacey RB, Andersen MM, St Clair M, et al. Comparison of systolic and diastolic criteria for isolated LV noncompaction in CMR. *JACC Cardiovasc Imaging* 2013;**6**:931-40.
- 31 Tian T, Liu Y, Gao L, et al. Isolated left ventricular noncompaction: clinical profile and prognosis in 106 adult patients. *Heart Vessels* 2014;**29**:645-52.
- 32 Peters F, Khandheria BK, Botha F, et al. Clinical outcomes in patients with isolated left ventricular noncompaction and heart failure. *J Card Fail* 2014;**20**:709-15.
- 33 Li J, Franke J, Pribe-Wolferts R, et al. Effects of beta-blocker therapy on electrocardiographic and echocardiographic characteristics of left ventricular noncompaction. *Clin Res Cardiol* 2015;**104**:241-9.
- 34 Akhbour S, Fellat I, Fennich N, et al. Electrocardiographic findings in correlation to magnetic resonance imaging patterns in African patients with isolated ventricular noncompaction. *Anatol J Cardiol* 2015;**15**:550-5.
- 35 Stollberger C, Blazek G, Gessner M, et al. Age-dependency of cardiac and neuromuscular findings in adults with left ventricular hypertrabeculation/noncompaction. *Am J Cardiol* 2015;**115**:1287-92.
- 36 Amzulescu MS, Rousseau MF, Ahn SA, et al. Prognostic Impact of Hypertrabeculation and Noncompaction Phenotype in Dilated Cardiomyopathy: A CMR Study. *JACC Cardiovasc Imaging* 2015;**8**:934-46.
- 37 Minamisawa M, Koyama J, Kozuka A, et al. Regression of left ventricular hypertrabeculation is associated with improvement in systolic function and favorable prognosis in adult patients with non-ischemic cardiomyopathy. *J Cardiol* 2016;**68**:431-8.
- 38 Zhou H, Lin X, Fang L, et al. Characterization of Compacted Myocardial Abnormalities by Cardiac Magnetic Resonance With Native T1 Mapping in Left Ventricular Non-Compaction Patients- A Comparison With Late Gadolinium Enhancement. *Circ J* 2016;**80**:1210-6.
- 39 Andreini D, Pontone G, Bogaert J, et al. Long-Term Prognostic Value of Cardiac Magnetic Resonance in Left Ventricle Noncompaction: A Prospective Multicenter Study. *J Am Coll Cardiol* 2016;**68**:2166-81.

- 40 Muser D, Liang JJ, Witschey WR, et al. Ventricular arrhythmias associated with left ventricular noncompaction: Electrophysiologic characteristics, mapping, and ablation. *Heart Rhythm* 2017;**14**:166-75.
- 41 Asfalou I, Boulaamayi S, Raissouni M, et al. Left ventricular noncompaction-A rare form of cardiomyopathy: Revelation modes and predictors of mortality in adults through 23 cases. *J Saudi Heart Assoc* 2017;**29**:102-9.
- 42 Tavares de Melo MD, Giorgi MCP, Assuncao AN, Jr., et al. Decreased glycolytic metabolism in non-compaction cardiomyopathy by 18F-fluoro-2-deoxyglucose positron emission tomography: new insights into pathophysiological mechanisms and clinical implications. *Eur Heart J Cardiovasc Imaging* 2017;**18**:915-21.
- 43 Mazurkiewicz L, Petryka J, Spiewak M, et al. Clinical and prognostic relevancy of left ventricular trabeculation assessed by cardiac magnetic resonance in patients with dilated cardiomyopathy. *Kardiol Pol* 2017;**75**:794-803.
- 44 Sedaghat-Hamedani F, Haas J, Zhu F, et al. Clinical genetics and outcome of left ventricular non-compaction cardiomyopathy. *Eur Heart J* 2017;**38**:3449-60.
- 45 Salazar-Mendiguchia J, Gonzalez-Costello J, Oliveras T, et al. Long-term Follow-up of Symptomatic Adult Patients With Noncompaction Cardiomyopathy. *Rev Esp Cardiol (Engl Ed)* 2019;**72**:169-71.
- 46 Martinez HR, Ware SM, Schamberger MS, et al. Noncompaction cardiomyopathy and heterotaxy syndrome. *Prog Pediatr Cardiol* 2017;**46**:23-7.
- 47 Araujo-Filho JAB, Assuncao AN, Jr., Tavares de Melo MD, et al. Myocardial T1 mapping and extracellular volume quantification in patients with left ventricular non-compaction cardiomyopathy. *Eur Heart J Cardiovasc Imaging* 2018;**19**:888-95.
- 48 Sohns C, Ouyang F, Volkmer M, et al. Therapy of ventricular arrhythmias in patients suffering from isolated left ventricular non-compaction cardiomyopathy. *Europace* 2019;**21**:961-9.
- 49 van Waning JJ, Caliskan K, Michels M, et al. Cardiac Phenotypes, Genetics, and Risks in Familial Noncompaction Cardiomyopathy. *J Am Coll Cardiol* 2019;**73**:1601-11.
- 50 Azevedo O, Marques N, Craveiro N, et al. Screening for Fabry disease in patients with left ventricular noncompaction. *Rev Port Cardiol* 2019;**38**:709-16.
- 51 Macaione F, Meloni A, Positano V, et al. The planimetric Grothoff's criteria by cardiac magnetic resonance can improve the specificity of left ventricular non-compaction diagnosis in thalassemia intermedia. *Int J Cardiovasc Imaging* 2020;**36**:1105-12.
- 52 Asmakutlu O, Alis D, Topel C, et al. Late gadolinium enhancement on CMRI in patients with LV noncompaction: An overestimated phenomenon? *Clin Imaging* 2020;**66**:121-6.
- 53 Rocon C, Tabassian M, Tavares de Melo MD, et al. Biventricular imaging markers to predict outcomes in non-compaction cardiomyopathy: a machine learning study. *ESC Heart Fail* 2020;**7**:2431-9.
- 54 Rapatz K, Finsterer J, Voill-Glaninger A, et al. NT-pro-BNP in patients with left ventricular hypertrabeculation/non-compaction. *ESC Heart Fail* 2020.
- 55 Zemrak F, Raisi-Estabragh Z, Khanji MY, et al. Left Ventricular Hypertrabeculation Is Not Associated With Cardiovascular Morbidity or Mortality: Insights From the Eurocmr Registry. *Front Cardiovasc Med* 2020;**7**:158.
- 56 Femia G, Zhu D, Choudhary P, et al. Long term clinical outcomes associated with CMR quantified isolated left ventricular non-compaction in adults. *Int J Cardiol* 2021;**328**:235-40.
- 57 Galizio NOG, José L.;Favaloro, Liliana E.;Diez, Mirta;Fernández, Adrián;Guevara, Eduardo;Palazzo, Alejandro A.;Robles, Federico;Casabé, José H.;Galizio, N. O. Non-compaction cardiomyopathy. Risk stratification of Sudden death for automatic cardioverter defibrillator implantation. *REV ARGENT CARDIOL* 2011;**79**:7.